Since emerging in prominence on the party scene in the 1980s, ecstasy has become a staple of festival and rave culture. But the drug also carries far more risks today than it did back then − and some ...
Lykos Therapeutics, whose lead asset, midomafetamine capsules (MDMA), failed to win the FDA nod in August, said that the regulator has indicated a path forward for the Ecstasy-based drug, which, if ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback